Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0015672 (fatigue)
 51,768 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fatigue and activity intolerance are reported to persist for several weeks after discharge after coronary artery bypass graft (CABG) surgery. This may be due to early discharge, which limits the time, prior to leaving hospital, to achieve an adequate functional level for the performance of many activities of daily living. Alternatively, it may be related to level of self-confidence, or self-efficacy (SE), in one's ability to perform physical activity. High SE may result in overexertion during the vulnerable, early post-discharge phase of recovery, whereas low SE may cause underexertion. The limited number of cardiac rehabilitation programs in Canada for this phase of recovery precludes close guidance and monitoring during physical activity for most patients. Prior to prescribing safe and effective home exercise at discharge, it is essential to assess functional level, cardiovascular responses to physical activity, and perceived level of confidence in ability to perform physical activity. The purpose of this descriptive study was to measure functional capacity, hemodynamic responses to low level exercise, and self-efficacy at discharge after CABG surgery. Twenty-one men completed a self-efficacy questionnaire (SEQ) and a low-level graded exercise test (LL-GXT) using a modified Naughton protocol, on the day of discharge. Results revealed that discharge functional capacity ranged from 1.0 METs to 4.3 METs, peak heart rate ranged from 82-150 beats.min-1, and peak systolic blood pressure from 114-200 mmHg. Subjects were more confident in their ability to tolerate psychological stressors than physical activity. Furthermore, there was no correlation between SE for physical activity and the physiological variables except HR.(ABSTRACT TRUNCATED AT 250 WORDS)
Can J Cardiovasc Nurs
PMID:Discharge functional capacity and self-efficacy of men after coronary artery bypass graft surgery. 130 Oct 76

Patients treated with beta-blocking agents often complain of fatigue during exercise. Exercise capacity is decreased under this condition. Nebivolol is a new beta 1-adrenoceptor antagonist with a particular hemodynamic profile, which might be due to an ancillary property. Five milligrams once daily seems the optimal dose for antihypertensive treatment. In a double-blind, placebo-controlled crossover study, the effects of nebivolol on maximal and endurance exercise capacity are compared with those of atenolol in healthy volunteers. The hemodynamic and metabolic effects during exercise are also studied. Nebivolol 5 mg once daily and atenolol 100 mg once daily decrease blood pressure at rest similarly. At these dosages nebivolol shows a smaller decrease in heart rate than atenolol. During exercise, the rise in systolic blood pressure and heart rate is less depressed with nebivolol than with atenolol. In contrast to atenolol, nebivolol does not decrease maximal and endurance exercise capacity, and does not increase perceived exertion significantly. Changes in hemodynamics influence maximal exercise capacity. Since nebivolol has less effect on exercise hemodynamics than atenolol, this might explain why maximal work capacity is not changed during nebivolol. During endurance exercise metabolic effects are thought to be more important. Under nebivolol glycerol and NEFA production is less depressed during exercise and might explain the preserved endurance capacity. These data suggest less beta blockade during nebivolol than during atenolol at the dosages used in this study. In conclusion, at a dose known to be antihypertensive, nebivolol does not alter exercise capacity significantly in healthy volunteers.
Cardiovasc Drugs Ther 1992 Jun
PMID:Exercise tolerance with nebivolol and atenolol. 135 67

Output power and metabolic input power values were determined for unconditioned canine latissimus dorsi (two), gastrocnemius (seven), and triceps (three) muscles contracting linearly to cause compression of a doubly valved pouch in a hydraulic model of the circulation. The motor nerves to the muscles were stimulated tetanically with 450 msec trains of 0.1 msec pulses having a frequency of 50/sec. The muscles were contracted 10, 20, 30, and 40 times per minute and pouch output in milliliters per minute was measured directly for each muscle at each contraction (train) rate. The output power in milliwatts was determined by two methods: (1) by using the pouch output and the pressure rise imparted to the stroke volume (average power) and (2) by using the pressure-volume loop. Metabolic input power in milliwatts was determined from the oxygen consumption in milliliters per minute of the working muscle. It was found that as the pouch output was increased, the pouch output power and the metabolic input power both increased. The average power output was slightly less than that computed from the pressure-volume loop. The mean output power values, when pumping at L liters per minute, were 0.62 L (average) and 0.75 L mW/gm (pressure-volume loop) for the latissimus dorsi muscles; 0.83 L (average) and 1.16 L mW/gm (pressure-volume loop) for the gastrocnemius muscles; and 0.55 L (average) and 0.66 L mW/gm (pressure-volume loop) for the triceps muscles. The percent efficiency of energy conversion ranged from 9.2% to 17.8% for the latissimus dorsi muscles, from 5.1% to 19.5% for the gastrocnemius muscles, and from 10.5% to 27.3% for the triceps muscles. However, it should not be concluded that one muscle type is better than another on the basis of percent efficiency because efficiency does not take endurance into account. An important observation in this study relates to the large output obtained with the three linearly contracting muscle types. All were capable of pumping in excess of 1.5 L/min. A second observation relates to the absence of fatigue, although determination of endurance was not an objective in these studies.
J Thorac Cardiovasc Surg 1992 Nov
PMID:Output power and metabolic input power of skeletal muscle contracting linearly to compress a pouch in a mock circulatory system. 143 27

This report assesses the validity of subscales from the Quality of Life Index (QLI). Subscale validity is tested across different samples of patients with cancer and other diseases. The results of the factor analyses of different versions of the QLI tested in six studies confirm four important health-related quality of life dimensions. These dimensions are psychological well-being, physical well-being, symptoms/side effects, and nutrition. Psychological well-being is represented by a satisfying life, having a good (general) quality of life, having fun, feeling happy and enjoying life. Physical well-being is defined by tiring easily (fatigue), ability to work/carry out usual tasks, strength, and feeling healthy. The symptoms/side effects dimension is characterized by nausea, vomiting, pain distress, and perhaps, by pain amount and pain frequency. Finally, the nutrition dimension is represented by able to eat/eat sufficiently, eating pleasure/appetite, worry about weight, and possibly also taste changes. Good construct validity can be attributed to these health-related quality of life subscales.
Prog Cardiovasc Nurs
PMID:Validity of health-related quality of life subscales. 151 79

To evaluate electrically stimulated muscle grafts for augmenting ventricular function in cardiac insufficiency, dynamic cardiomyoplasty was performed in nine sheep, using latissimus dorsi (LD) muscle wrapped as a pedicle around the left ventricle. Beginning 2 weeks postoperatively, LD was stimulated synchronously with the heart. After 6 and 12 weeks of stimulation, hemodynamic evaluation was done and biopsies were taken for histochemical and biochemical analysis. With intact heart function, stimulation of the muscle was not hemodynamically beneficial. During induced heart failure, cardiomyoplasty increased cardiac output by 25% in two sheep. Eight LD muscles contracted vigorously in synchrony with the heart, one was fibrosed and all were fixed to the thoracotomy incision by scar tissue. ATPase stain showed gradual transformation of muscle fibers into fatigue-resistant Type I. At 12 weeks only Type I were seen. Quantitative enzymatic analyses revealed increase in oxidative and decrease in glycolytic enzymes. Chronic electrical stimulation is concluded to change the muscle characteristics towards those of mainly oxidative and fatigue-resistant muscle, thereby improving opportunities for assisting the depressed heart. Dynamic cardiomyoplasty involves risks of adhesions to adjacent tissues and muscle trauma from chronic stimulation.
Scand J Thorac Cardiovasc Surg 1992
PMID:Experimental dynamic cardiomyoplasty in sheep. 152 92

Autopsy or surgical specimens from six patients with primary cardiac angiosarcoma seen at the Mayo Clinic (all in men) between 1939 and 1988 were studied (patients' ages, 31 to 80 years; mean 50 years). The symptoms were nonspecific and included dyspnea and thoracoabdominal pain in six; anorexia in five; fatigue, hemoptysis, or orthopnea in four; nausea and vomiting, fever, or weight loss in three; and night sweats in two. Cardiomegaly was present in five, and a pericardial effusion or density, a mass adjacent to the heart, or nonspecific ST-T wave changes were present in three. All six neoplasms arose from the right atrium and exhibited epicardial or endocardial extension; three produced obstructive intracavitary right atrial masses. Pulmonary metastatic lesions were noted in five patients. The cardiac neoplasm was diagnosed by computed tomography or magnetic resonance imaging in the three most recent patients, and surgical resection was performed in two of them. Mean survival was 6 months after presentation. Causes of death were pulmonary hemorrhage in three, thoracic metastasis in two, and hemopericardium in one. The diagnosis of primary cardiac angiosarcoma was established at operation in two patients and at autopsy in four. Despite diagnosis by noninvasive imaging procedures and aggressive early surgical intervention, survival was less than 6 months. Thus optimal therapy is unclear.
J Thorac Cardiovasc Surg 1992 Apr
PMID:Primary cardiac angiosarcoma: a clinicopathologic study of six cases. 154 8

Tricuspid valvular insufficiency caused by blunt thoracic trauma may be clinically silent and imprecise. Diagnosis is often done by cardiac catheterization and two-dimensional echocardiography (2-DE); the latter may show abnormalities of the tricuspid leaflet motion. The surgical technique for its correction is still controversial. We report here the case of an eighteen year old man who was involved in a high-speed motorcycle accident. Seven months later, due to dyspnoea and fatigue, 2D-E examination revealed cardiac enlargement and severe tricuspid regurgitation. Surgery was indicated in order to repair valve incompetence. Reinsertion of the chordae tendineae at the anterolateral papillary muscle and annuloplasty was performed and ten months postoperatively, he is in good clinical condition and 2D-E control shows a trivial residual tricuspid insufficiency.
J Cardiovasc Surg (Torino)
PMID:Traumatic tricuspid regurgitation. 157 90

Enalapril is an effective agent in the treatment of mild to severe hypertension. It is equally effective in elderly and young adult patients but appears to be more effective in white than in black hypertensive patients. Following treatment with enalapril, an assessment of maximum exercise performance found a decrease in total peripheral resistance without significant changes in cardiac output, heart rate, or stroke volume compared with pretreatment values. In addition, there have been reports of reversal of left ventricular hypertrophy in enalapril-treated hypertensive patients. Enalapril is also effective and well tolerated in hypertensive patients with renal impairment of varying etiology. The most common adverse experiences reported in controlled clinical trials were headache (5.2%), dizziness (4.3%), and fatigue (3.0%). In high-risk hypertensive patients, no enalapril-treated neutropenia, proteinuria, dysgeusia, or ageusia were reported. It may be concluded that the benefit-to-risk ratio of enalapril is among the best of the antihypertensive therapies currently available.
J Cardiovasc Pharmacol 1990
PMID:Enalapril: benefit-to-risk ratio in hypertensive patients. 169 15

Felodipine is a dihydropyridine that blocks the slow entry channel for calcium. It is highly vascular selective and reduces blood pressure (BP) by dilatation of peripheral arterioles. It reduces BP in mild, moderate, and severe hypertension, and the fall in BP depends upon the initial level. It has been compared with a variety of other drugs as monotherapy or as add-on therapy. In these studies, felodipine (10-40 mg/day) has caused a similar or greater fall in BP and a similar or greater percentage of patients have achieved a diastolic BP less than or equal to 90 mm Hg. The plain tablet of felodipine needs to be given twice a day but an extended-release form can be given once daily. Some patients respond to 5 mg/day and most patients respond to a daily dose of 20 mg or less. The adverse effects are few except for a constellation of symptoms related to the vasodilator ability of the drug. These include palpitations, flushing, fatigue, dizziness, and headaches. These occur, if at all, usually within the first 2 weeks and diminish as the drug is continued. They can be limited by starting on a small dose of felodipine (5 mg/day). People who have these adverse effects usually have a good response to the drug. Another adverse effect, which is the most frequent reason for drug withdrawal, is ankle edema. This is more common on the higher doses of the drug. It is due to dilatation of the precapillary resistance vessels rather than sodium and water retention. Felodipine is a useful and effective antihypertensive drug and can be used as monotherapy or added to other antihypertensive drugs. It is effective in people with all grades of hypertension.
J Cardiovasc Pharmacol 1990
PMID:A review of the antihypertensive effects of felodipine alone or in combination. 169 35

The effects on exercise tolerance of 7-day treatment with a calcium channel blocker, verapamil 160 mg twice daily (b.i.d.), and a beta 1-selective blocker, atenolol 50 mg b.i.d., were compared in 10 healthy and physically active young subjects in 5,000-m cross-country running at high intensity. The study was a double-blind cross-over trial. Comparison was made with a single-blind placebo as well. Performance time was measured every 1,000 m in seven 5,000-m runs, in which subjects were instructed to keep to a constant fatigue perception (Borg scale rating). Both drugs significantly (p = 0.001) increased the performance time over the first 1,000 m as compared with placebo. However, running time after 1,000, 2,000, and 3,000 m was prolonged significantly less (p less than 0.05) by verapamil than by atenolol. For the entire 5,000-m run, atenolol caused a significant increase (p = 0.001) in mean running time by 1 min 34 s (i.e., 7.5%; 95% confidence interval 48 s to 2 min 21 s) as compared with placebo, whereas verapamil caused no significant change (+46 s).
J Cardiovasc Pharmacol 1990 Jul
PMID:Effects of verapamil and atenolol on exercise tolerance in 5,000 m cross-country running: a double-blind cross-over study in normal humans. 169 62


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>